Neutralizing antibody response and antibody-dependent cellular cytotoxicity in HIV-1-infected individuals from Guinea-Bissau and Denmark Institute of Tropical Medicine
The development of therapeutic and prophylactic HIV vaccines for African countries is urgently needed, but the question of what immunogens to use needs to be answered. One approach is to include HIV envelope immunogens derived from HIV-positive individuals from a geographically concentrated epidemic with more limited viral genetic diversity for a region-based vaccine. To address if there is a basis for a regional selected antibody vaccine, we ...